Kalray Showcases Leading Solutions for High-performance Computing and Unstructured Data at Dell Technologies World 2023
27.4.2023 18:45:00 EEST | Business Wire | Press release
Kalray (Euronext Growth Paris: ALKAL) , a leading provider of hardware and software technologies and solutions for high-performance data-centric computing markets, from Cloud to Edge, is pleased to announce its presence at Dell Technologies World as a Dell ETC Partner, from May 22 to 25, 2023, in Las Vegas.
Dell Technologies World (DTW) is a major annual event that brings together industry leaders, experts, and customers to discuss the latest trends and innovations in technology. The event covers a wide range of topics and attracts thousands of attendees from around the world.
Kalray will be exhibiting at DTW as a Dell Technologies ETC Partner. The ETC program is a Dell Technologies partnership program delivering all-in-one solutions, combining selected ETC partner solutions with Dell Technologies servers, storage, and networking, to create an industry-leading value proposition.
With its solutions, Kalray addresses the challenges of data-intensive workloads for use cases such as Artificial Intelligence, Machine Learning, High-Performance Computing, IoT processing, and unstructured data. Primary verticals are Life Sciences, Manufacturing, Higher Education, and Finance. All have requirements to process and manage unstructured data in a fast and efficient way, wherever the data resides.
“This is a great opportunity for Kalray to demonstrate our unique portfolio for HPC and Unstructured Data Solutions, to enterprise customers," says Kalray CEO, Éric Baissus. “The exhibition booth and joint presentation activities at Dell Technologies World is part of our strategy to accelerate our go-to-market and strengthen our offering with Dell Technologies."
pixstor™ with ngenea® , combined with Dell Technologies solutions, provides customers an all-in-one, easy-to-use solution that meets the requirements of demanding storage workloads. pixstor’s™ “Tier-Zero” scratch storage enables customers to dramatically increase storage performance, while ngenea® vastly improves efficiency by consolidating storage environments such as Dell PowerScale and ECS, simplifying data management workflows.
Associated with Kalray’s DPU-based cards , Kalray provides a unique hardware and software storage offering.
At Dell Technologies World, attendees can learn more about Kalray’s award-winning solutions at booth #1729. The Kalray team will be showcasing several live product demos:
- pixstor™ Search finds data across an entire data namespace, without opening a single file. Bring users closer to their data and reducing time spent locating files.
- Discover ngenea®2 self-service for the world of HSM (Hierarchical storage Management). Watch live as ngenea®2 controls site-to-site replication and cloud bursting, without needing administrative privileges or cloud expertise.
- Global Sync- Distributed workflow challenges call for a distributed workflow solution. Keep your global footprint in sync and up to date, even with hundreds of thousands of changes per hour.
- Kalray will be also introducing a high-performance NVMe-based Tier-0 storage solution based on its DPU (Data Processing Unit) acceleration cards and Dell Technologies server. Designed for data-intensive workloads and applications, this solution offers unique benefits in term of performance per watt and performance per dollar.
Register your interest in our product showcase or book a meeting with our technical experts here:
https://www.kalrayinc.com/dtw-2023
About KALRAY
Kalray is a leading provider of hardware and software technologies and solutions for high-performance, data centric computing markets, from Cloud to Edge. Kalray provides a full range of products to enable smarter, more efficient, and energy-wise data-intensive applications and infrastructures.
Its offers include its unique patented DPU (Data Processing Unit) processors and acceleration cards as well as its leading-edge software-defined storage and data management offers. Separated or in combination, Kalray’s high-performance solutions allow its customers to improve the efficiency of data centers or design the best solutions in fast-growing sectors such as AI, Media & Entertainment, Life Sciences, Scientific Research, Edge Computing, Automotive and others.
Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors or Bpifrance, Kalray is dedicated through technology, expertise, and passion to offer more: more for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230427005601/en/
Contact information
INVESTOR CONTACTS
Eric BAISSUS
contactinvestisseurs@kalrayinc.com
Phone: + 33 4 76 18 90 71
ACTUS Finance & Communication
Anne-Pauline PETUREAUX
kalray@actus.fr
Phone: + 33 1 53 67 36 72
PRESS CONTACTS
Sylvie DAM
communication@kalrayinc.com
Phone: +33 4 76 18 90 71
ACTUS Finance & Communication
Serena BONI
sboni@actus.fr
Phone: +33 4 72 18 04 92
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom